Toll-like receptor agonists have hit another setback with the Phase II failure of Idera's IMO-2055, but these immunotherapies may still make a comeback if appropriate combinations with vaccine ...

Even in today’s world of smartphones, tablets, and smartwatches, the miniaturization of technology is limited by power demand. No matter how small we can make the circuitry, the batteries still have ...